Literature DB >> 21094621

Overexpression of adapted U1snRNA in patients' cells to correct a 5' splice site mutation in propionic acidemia.

Rocío Sánchez-Alcudia1, Belén Pérez, Celia Pérez-Cerdá, M Ugarte, Lourdes R Desviat.   

Abstract

Splicing defects account for 16% of the mutant alleles in the PCCA and PCCB genes, encoding both subunits of the propionyl-CoA carboxylase (PCC) enzyme, defective in propionic acidemia, one of the most frequent organic acidemias causing variable neurological impairment. Most of the splicing mutations identified affect the conserved 3' splice (3' ss) or 5' splice (5' ss) sites, the latter predictably through lowering the strength of base pairing with U1snRNA. Among the 5' ss mutations we have focused on the c.1209+3A>G (IVS13+3A>G) mutation in the PCCA gene, identified in four patients (three homozygous and one heterozygous) of common geographical origin and causing exon 13 skipping. To study the potential of splicing modulation to restore PCC function, we analyzed the effect of transient transfections in patients' cells with modified U1snRNA adapted to compensate the mutant change and other mismatches at different positions of the 5' ss. Using this strategy normal transcript could be efficiently recovered with the concomitant disappearance of the aberrant exon skipping transcript, as observed after standard RT-PCR and sequence analysis or using fluorescent primers and semiquantitative RT-PCR. Different efficiencies with up to 100% exon inclusion were observed depending on the transfection conditions and specifically on the adapted U1snRNA used, confirming previously reported dependencies between nucleotides at the 5' ss for its correct recognition by the spliceosome. The reversal of the splicing defect did not result in a significant increase in enzyme activity, suggesting other factors must be taken into account for the application of overexpression of splice factors such as U1 as therapeutic strategy for splice defects.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21094621     DOI: 10.1016/j.ymgme.2010.10.013

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  9 in total

Review 1.  Therapeutic approaches to treat human spliceosomal diseases.

Authors:  Anthony B DeNicola; Yi Tang
Journal:  Curr Opin Biotechnol       Date:  2019-02-15       Impact factor: 9.740

Review 2.  Structure and function of biotin-dependent carboxylases.

Authors:  Liang Tong
Journal:  Cell Mol Life Sci       Date:  2012-08-07       Impact factor: 9.261

Review 3.  Targeting RNA splicing for disease therapy.

Authors:  Mallory A Havens; Dominik M Duelli; Michelle L Hastings
Journal:  Wiley Interdiscip Rev RNA       Date:  2013-03-19       Impact factor: 9.957

4.  Therapeutic strategies based on modified U1 snRNAs and chaperones for Sanfilippo C splicing mutations.

Authors:  Liliana Matos; Isaac Canals; Larbi Dridi; Yoo Choi; Maria João Prata; Peter Jordan; Lourdes R Desviat; Belén Pérez; Alexey V Pshezhetsky; Daniel Grinberg; Sandra Alves; Lluïsa Vilageliu
Journal:  Orphanet J Rare Dis       Date:  2014-12-10       Impact factor: 4.123

5.  Improvement of SMN2 pre-mRNA processing mediated by exon-specific U1 small nuclear RNA.

Authors:  Andrea Dal Mas; Malgorzata Ewa Rogalska; Erica Bussani; Franco Pagani
Journal:  Am J Hum Genet       Date:  2014-12-31       Impact factor: 11.025

6.  Exon Skipping Through Chimeric Antisense U1 snRNAs to Correct Retinitis Pigmentosa GTPase-Regulator (RPGR) Splice Defect.

Authors:  Giuseppina Covello; Gehan H Ibrahim; Niccolò Bacchi; Simona Casarosa; Michela Alessandra Denti
Journal:  Nucleic Acid Ther       Date:  2022-02-14       Impact factor: 4.244

7.  Therapeutic activity of modified U1 core spliceosomal particles.

Authors:  Malgorzata Ewa Rogalska; Mojca Tajnik; Danilo Licastro; Erica Bussani; Luca Camparini; Chiara Mattioli; Franco Pagani
Journal:  Nat Commun       Date:  2016-04-04       Impact factor: 14.919

8.  An Exon-Specific U1snRNA Induces a Robust Factor IX Activity in Mice Expressing Multiple Human FIX Splicing Mutants.

Authors:  Dario Balestra; Daniela Scalet; Franco Pagani; Malgorzata Ewa Rogalska; Rosella Mari; Francesco Bernardi; Mirko Pinotti
Journal:  Mol Ther Nucleic Acids       Date:  2016-10-04       Impact factor: 10.183

9.  Combining Engineered U1 snRNA and Antisense Oligonucleotides to Improve the Treatment of a BBS1 Splice Site Mutation.

Authors:  Saskia Breuel; Mariann Vorm; Anja U Bräuer; Marta Owczarek-Lipska; John Neidhardt
Journal:  Mol Ther Nucleic Acids       Date:  2019-08-16       Impact factor: 8.886

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.